Bivirkningerne, der ses ved hepatitis C, er repræsentative for dem, der rapporteres, når IntronA gives ved andre indikationer, med nogle forventede dosisrelaterede stigninger i incidensen.
The undesirable effects seen with hepatitis C are representative of those reported when IntronA is administered in other indications, with some anticipated dose-related increases in incidence.